Creative Medical Technology Holdings Inc CELZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
-
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
-
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
-
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.68–0.78
- 52-Week Range
- $0.62–6.25
- Bid/Ask
- $0.72 / $0.78
- Shares Outstanding
- 7.59M
- Market Cap
- $5.73M
- Volume/Avg
- 3,199 / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 778.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
Valuation
|
Metric
|
CELZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | 778.04 |
Price/Cash Flow | — |
Price/Earnings
CELZ
Financial Strength
|
Metric
|
CELZ
|
|---|---|
Quick Ratio | 12.81 |
Current Ratio | 12.91 |
Interest Coverage | — |
Quick Ratio
CELZ
Profitability
|
Metric
|
CELZ
|
|---|---|
Return on Assets (Normalized) | −82.53% |
Return on Equity (Normalized) | −87.02% |
Return on Invested Capital (Normalized) | −89.77% |
Return on Assets
CELZ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|S#fL#k | LOCK|C>pfW | $130B | |||
| Moderna Inc
MRNA
| LOCK|Sy?#Yb$ | LOCK|$p | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^%ZmY&Q | LOCK|??^% | $83B | |||
| argenx SE ADR
ARGX
| LOCK|HL%$Mn$ | LOCK|qK | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$PF<<n | LOCK|vy | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<%!#p& | LOCK|nJQ? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$?#fcbw | LOCK|Q&<%! | $28B | |||
| Incyte Corp
INCY
| LOCK|j#hlx? | LOCK|^c^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|cl^Bfc | LOCK|$d | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!z##n% | LOCK|w@ | $14B |
United States